Response to immunomodulator treatment as diagnostic criterion of cirrhosis due to autoimmune hepatitis

Joint Event on 13^th International Conference on ARTHRITIS AND RHEUMATOLOGY & 3^rd International Conference on ANATOMY AND PHYSIOLOGY

December 9-10, 2019 | Barcelona, Spain

Laura Camila Caceres

Universidad Autonoma de Bucaramanga, Colombia

Posters & Accepted Abstracts: J Orthop Trauma Surg Rel Res

Abstract :

Autoimmune hepatitis is a progressive inflammatory disease that directly attacks the hepatocytes, in the long term and without timely treatment leads to cirrhosis. Worldwide, it is estimated between 11.6-35.9 cases/100,000 inhabitants, therefore, in medical practice it is low considered in the diagnosis of chronic hepatitis; because the simplified diagnostic criteria for this disease are complex, since they focus on expensive diagnostic means and in low and middle income countries, access is difficult, the opportunity for diagnosis and treatment is also important Consider the sensitivity of these. In addition, it is important to consider the sensitivity of these diagnostic means. Some cases are atypical, in which clinical improvement with immunomodulatory treatment is highlighted as a diagnostic criterion of the classic criteria of 1999 to establish the diagnosis of autoimmune hepatitis due to the high sensitivity of the response to treatment evidenced at 48 hours. Therefore, it is important to consider the start of immunomodulatory treatment against autoimmune hepatitis once the main causes of chronic liver disease have been ruled out, despite not fulfilling the diagnostic criteria, as this prevented progression of the disease, a fatal outcome and mortality in the patient. The absence of immunosuppressive therapy between diagnostic criteria is a limitation for diagnosis and treatment.

Biography :

E-mail: lcaceres674@gmail.com